Status:
COMPLETED
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
Lead Sponsor:
Allergan
Conditions:
Benign Prostatic Hyperplasia
Eligibility:
MALE
50+ years
Phase:
PHASE2
Brief Summary
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
Eligibility Criteria
Inclusion
- Lower urinary tract symptoms due to benign prostatic hyperplasia
- Enlarged prostate volume by rectal ultrasound
Exclusion
- Previous prostate surgery
- Previous or current diagnosis of prostate cancer
- Use of other medications for the treatment of prostatic hyperplasia
- Urinary tract infection
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
380 Patients enrolled
Trial Details
Trial ID
NCT00284518
Start Date
December 1 2005
End Date
May 1 2010
Last Update
December 17 2012
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Murdoch, Australia
2
Vienna, Austria
3
Victoria, British Columbia, Canada
4
Olomouc, Czechia